Daily use of a prescription-grade fish oil pill, first marketed by GlaxoSmithKline before going generic, failed to prevent serious cardiovascular events or death in people with diabetes, according to results from a large clinical trial presented Sunday.

The negative outcome of the study, called ASCEND, adds to the growing body of scientific evidence casting doubt on the long-term heart benefit of products containing omega-3 fatty acids.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • The study was flawed. The people mostly were already compromised. Fish oil isn’t gonna cure or help people who are sick.
    It’s an ongoing positive addition that helps. But it’s not a cure.
    Also I read somewhere that the study did not include sudden deaths. Which makes no sense, and I’m not sure I read that right.
    Need to check into it more.
    Fish oil helps make blood slippery so maybe the deposits don’t stick. At least that’s what I hear. Works here.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy